Charles Schwab Investment Management Inc Biotechnology

Charles Schwab Investment Management Inc

$521 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
SAGE Sage Therapeutics, Inc.	$521M	$3.55 Million 0.0% of portfolio	446,178	Q1 2025 Reduced 3.49%
ARVN Arvinas, Inc.	$420M	$3.43 Million 0.0% of portfolio	489,239	Q1 2025 Reduced 8.74%
NUVB Nuvation Bio Inc.	$545M	$3.35 Million 0.0% of portfolio	1,904,141	Q1 2025 Reduced 2.15%
CGEM Cullinan Oncology, Inc.	$380M	$3.21 Million 0.0% of portfolio	424,262	Q1 2025 Reduced 1.56%
QURE Uni Qure N.V.	$711M	$2.97 Million 0.0% of portfolio	279,999	Q1 2025 Added 3.71%
ARGX Argenx Se	$32.7B	$2.8 Million 0.0% of portfolio	4,732	Q1 2025 Added 12.29%
RLAY Relay Therapeutics, Inc.	$442M	$2.79 Million 0.0% of portfolio	1,064,858	Q1 2025 Added 5.35%
SVRA Savara Inc	$291M	$2.64 Million 0.0% of portfolio	954,830	Q1 2025 Reduced 0.93%
RGNX Regenxbio Inc.	$395M	$2.62 Million 0.0% of portfolio	366,549	Q1 2025 Added 4.81%
VERV Verve Therapeutics, Inc.	$667M	$2.6 Million 0.0% of portfolio	568,184	Q1 2025 Reduced 0.44%
TBPH Theravance Biopharma, Inc.	$743M	$2.57 Million 0.0% of portfolio	287,716	Q1 2025 Reduced 2.12%
KROS Keros Therapeutics, Inc.	$370M	$2.47 Million 0.0% of portfolio	241,923	Q1 2025 Reduced 13.5%
HRTX Heron Therapeutics, Inc.	$226M	$2.4 Million 0.0% of portfolio	1,089,449	Q1 2025 Reduced 1.48%
CELC Celcuity Inc.	$206M	$2.35 Million 0.0% of portfolio	232,036	Q1 2025 Reduced 2.39%
XERS Xeris Biopharma Holdings, Inc.	$703M	$2.33 Million 0.0% of portfolio	423,775	Q1 2025 Added 5.19%
ORIC Oric Pharmaceuticals, Inc.	$457M	$2.28 Million 0.0% of portfolio	408,505	Q1 2025 Reduced 2.26%
VNDA Vanda Pharmaceuticals Inc.	$271M	$2.18 Million 0.0% of portfolio	475,865	Q1 2025 Reduced 14.79%
PHAT Phathom Pharmaceuticals, Inc.	$355M	$2.18 Million 0.0% of portfolio	348,035	Q1 2025 Reduced 1.42%
MRVI Maravai Lifesciences Holdings, Inc.	$356M	$2.1 Million 0.0% of portfolio	950,747	Q1 2025 Added 4.88%
TSVT 2seventy Bio, Inc.	$189M	$2.06 Million 0.0% of portfolio	417,950	Q1 2025 Reduced 2.5%
STOK Stoke Therapeutics, Inc.	$533M	$2.06 Million 0.0% of portfolio	310,307	Q1 2025 Reduced 9.3%
ARCT Arcturus Therapeutics Holdings Inc.	$397M	$2.06 Million 0.0% of portfolio	194,629	Q1 2025 Reduced 6.34%
ERAS Erasca, Inc.	$209M	$1.98 Million 0.0% of portfolio	1,441,656	Q1 2025 Reduced 18.21%
AVIR Atea Pharmaceuticals, Inc.	$311M	$1.82 Million 0.0% of portfolio	607,882	Q1 2025 Reduced 7.83%
PGEN Precigen, Inc.	$333M	$1.81 Million 0.0% of portfolio	1,216,764	Q1 2025 Reduced 4.86%
SANA Sana Biotechnology, Inc.	$976M	$1.79 Million 0.0% of portfolio	1,066,304	Q1 2025 Added 0.93%
ABSI Absci Corp	$326M	$1.75 Million 0.0% of portfolio	695,895	Q1 2025 Reduced 4.55%
TRDA Entrada Therapeutics, Inc.	$200M	$1.74 Million 0.0% of portfolio	192,717	Q1 2025 Reduced 2.24%
ALLO Allogene Therapeutics, Inc.	$217M	$1.69 Million 0.0% of portfolio	1,155,844	Q1 2025 Reduced 2.78%
ATXS Astria Therapeutics, Inc.	$99.9M	$1.68 Million 0.0% of portfolio	315,016	Q1 2025 Reduced 2.34%
GLUE Monte Rosa Therapeutics, Inc.	$267M	$1.68 Million 0.0% of portfolio	361,535	Q1 2025 Reduced 2.41%
ENOB Enochian Biosciences Inc	$244M	$1.67 Million 0.0% of portfolio	362,126	Q4 2024 Added 82.0%
TYRA Tyra Biosciences, Inc.	$452M	$1.53 Million 0.0% of portfolio	164,108	Q1 2025 Reduced 3.81%
ANNX Annexon, Inc.	$121M	$1.4 Million 0.0% of portfolio	725,752	Q1 2025 Reduced 2.43%
ITOS I Teos Therapeutics, Inc.	$361M	$1.39 Million 0.0% of portfolio	233,561	Q1 2025 Added 17.25%
AMLX Amylyx Pharmaceuticals, Inc.	$461M	$1.32 Million 0.0% of portfolio	372,853	Q1 2025 Added 24.72%
OLMA Olema Pharmaceuticals, Inc.	$187M	$1.31 Million 0.0% of portfolio	349,023	Q1 2025 Added 4.83%
HUMA Humacyte, Inc.	$275M	$1.31 Million 0.0% of portfolio	765,253	Q1 2025 Reduced 1.35%
TRVI Trevi Therapeutics, Inc.	$457M	$1.31 Million 0.0% of portfolio	207,518	Q1 2025 Added 19.91%
KALV Kal Vista Pharmaceuticals, Inc.	$384M	$1.31 Million 0.0% of portfolio	113,124	Q1 2025 Added 12.73%
GOSS Gossamer Bio, Inc.	$167M	$1.25 Million 0.0% of portfolio	1,138,947	Q1 2025 Reduced 8.3%
YMAB Y M Abs Therapeutics, Inc.	$212M	$1.23 Million 0.0% of portfolio	277,610	Q1 2025 Reduced 2.44%
AKBA Akebia Therapeutics, Inc.	$651M	$1.2 Million 0.0% of portfolio	622,914	Q1 2025 Added 6.17%
GMAB Genmab A/S	$15.6B	$1.19 Million 0.0% of portfolio	60,948	Q1 2025 Reduced 0.37%
FULC Fulcrum Therapeutics, Inc.	$407M	$1.1 Million 0.0% of portfolio	381,359	Q1 2025 Reduced 27.5%
CRMD Cor Medix Inc.	$480M	$1.09 Million 0.0% of portfolio	177,188	Q1 2025 Added 1.59%
CAPR Capricor Therapeutics, Inc.	$163M	$1.08 Million 0.0% of portfolio	113,650	Q1 2025 Added 2.08%
ALT Altimmune, Inc.	$201M	$1.06 Million 0.0% of portfolio	211,879	Q4 2024 Added 0.12%
EYPT Eye Point Pharmaceuticals, Inc.	$357M	$1.04 Million 0.0% of portfolio	191,144	Q1 2025 Reduced 0.01%
URGN Uro Gen Pharma Ltd.	$408M	$1.03 Million 0.0% of portfolio	93,547	Q1 2025 Added 0.03%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.